MACMILLAN, MUIR & ASSOCIATES DEFINING THE FIELD OF BRAIN MEDICINE EST. 2026
MacMillan, Muir & Associates
05FOR THE PRESS & EVENT ORGANIZERS

PRESS KIT

Everything a story needs. Except the spin.

Copy-ready biographies, portraits you can print, logos, the topics we speak on, our disclosures and recent coverage. Use anything here without asking. For interviews, comment on a story or a speaking request, write to info@macmillanmuir.com; we answer our own email.

BACK TO THE SITE

CARLENE MACMILLAN, MD, FCTMSS, DFAACAP

Carlene MacMillan.

One line. Carlene MacMillan, MD is a child, adolescent and adult psychiatrist, technologist, co-founder and former Chief Product Officer of Radial, who works to make Brain Medicine mainstream.

Short. Carlene MacMillan, MD is a psychiatrist, technologist, and co-founder and former Chief Product Officer of Radial. A leading voice in mental health technology, she builds coalitions across professional societies and industry, including the Clinical TMS Society, FACTMS and the APA, to make Brain Medicine mainstream.

Long. Carlene MacMillan, MD, FCTMSS, DFAACAP is a psychiatrist, technologist and one of the most prominent voices at the intersection of mental health care and health technology. She co-founded Radial, which is building the largest national network of advanced psychiatric treatment, and served as its Chief Product Officer. She continues to practice interventional child, adolescent and adult psychiatry with a focus on people who have not responded to standard care.

She earned her undergraduate and medical degrees at Harvard and completed her adult residency and child and adolescent fellowship at Massachusetts General Hospital and McLean Hospital. She is board-certified in adult psychiatry and in child and adolescent psychiatry. Before Radial she was Chief Medical Officer of Osmind, the electronic health record built for interventional and psychedelic psychiatry, and before that CEO and founding partner of Brooklyn Minds, which she and Owen Muir grew from two clinicians to about thirty, with roughly eighty staff, through to its acquisition. Brooklyn Minds was the first practice in New York City to offer esketamine when it was approved in 2019; her teams were the only East Coast site in the SAINT open-label study and delivered the first US course of Prism EEG-fMRI-guided neurofeedback for PTSD.

She co-chairs the Insurance Committee of the Clinical TMS Society and serves on its Executive Committee, sits on the board of the Foundation for the Advancement of Clinical TMS, helps lead the AACAP committee behind Facts for Families, serves on the APA's Committee on Quality and Performance Measurement, and is Vice President of the Ketamine Task Force. She hosts the Psychiatry Tomorrow podcast, speaks at conferences from the American Psychiatric Association to SXSW, has appeared on MSNBC and Soft White Underbelly, and writes for KevinMD, MedCity News and Psychedelic Alpha. Her peer-reviewed work includes the SWIFT accelerated deep TMS trial, real-world studies of TMS for OCD and depression, AI detection of tardive dyskinesia, and the first psychometric evaluation of the DSM-5-TR Level 1 Cross-Cutting measure in a real-world outpatient sample.

Disclosures: equity advisor to AMPA; consultant to EMOBOT; clinical advisory board, Ginko.

OWEN SCOTT MUIR, MD, DFAACAP, FCTMSS

Owen Muir.

One line. Owen Scott Muir, MD is a child, adolescent and adult psychiatrist, co-founder of Radial and author of The Frontier Psychiatrists, working on treatments that act in days rather than months.

Short. Owen Scott Muir, MD is a psychiatrist, co-founder and Chief Medical Officer of Radial, and Chief Medical Officer of Neurolief. Trained at Zucker Hillside Hospital and NYU/Bellevue, he researches rapid-acting treatments, including accelerated TMS, and writes The Frontier Psychiatrists, a near-daily newsletter on what psychiatry keeps getting wrong.

Long. Owen Scott Muir, MD, DFAACAP, FCTMSS is a psychiatrist, writer and company builder working on treatments that act in days rather than months. He is co-founder and Chief Medical Officer of Radial, Chief Medical Officer of Neurolief, and co-founder, with Grady Hannah, of RAMHT, the Rapid Acting Mental Health Treatment conference series held alongside JPM, the APA Annual Meeting and Psych Congress.

He earned a BA in psychology magna cum laude at Amherst College, completed postbaccalaureate premedical studies at the City College of New York and his MD at the University of Rochester, trained in general psychiatry at the Zucker Hillside Hospital (Hofstra-Northwell) and in child and adolescent psychiatry at NYU/Bellevue, and is board-certified in both. He is an official supervisor in Mentalization-Based Treatment and an AMBIT trainer with the Anna Freud National Centre for Children and Families in London, and a certified Good Psychiatric Management trainer. He has held faculty appointments at NYU and Baylor College of Medicine, worked in emergency psychiatry at Northwell and at Rockland Children's Psychiatric Center, and founded or co-founded Brooklyn Minds (acquired), Sphere Health (acquired) and Fermata, a neuromodulation-first clinic and research site in Brooklyn.

He is a co-author of the SWIFT trial of accelerated deep TMS for depression (Brain Stimulation, 2026), site principal investigator for Magnus Medical's SAINT open-label study, and senior author of the American Journal of Therapeutics' primer series on psychedelic therapy for primary care clinicians, where he serves on the editorial board. His newsletter and podcast, The Frontier Psychiatrists, is a Substack bestseller and SWAAY Health's 2025 Blog of the Year. He is the author of Thirty-Five Minutes: The Lindsay Clancy Mistrial and an After-Action Report for American Psychiatry and Inessential Pharmacology. He is a Distinguished Fellow of AACAP and a Fellow of the Clinical TMS Society, and has appeared in Soft White Underbelly, USA Today's America 250 series, HCPLive and The Guardian. He has spoken openly about his own treatment for bipolar depression, including with TMS.

Disclosures: advisory relationships with Ampa Health, Magnus Medical, Spring Health, Psyrin, Videra Health, Graymatters Health, Outro Health and Soniera Bio; research support from BrainsWay, Magnus Medical and MindMed.

PORTRAITS

Approved images.

Studio portraits, free to use with credit to MacMillan, Muir & Associates. Click to download the full-resolution file.

Carlene MacMillan, MD
Carlene MacMillan, MD · Download
Carlene MacMillan, MD
Carlene MacMillan, MD · Download
Owen Muir, MD
Owen Muir, MD · Download

LOGOS

Marks.

Use the logo as supplied; do not redraw the wave or recolor its segments. Primary logo (SVG) · Reversed logo for dark backgrounds (SVG). Palette: purple #2D174C, cypress #25473D, chartreuse #C5CB88, bone #FAF8F4.

SPEAKING TOPICS

What we can speak to.

  • Access to Brain Medicine: why TMS, esketamine and ketamine remain out of reach for most patients, and what closes the gap
  • Insurance coverage and prior authorization for neuromodulation and rapid-acting treatments
  • Accelerated TMS and SAINT, from trial data to community delivery
  • Psychedelic therapy: what practices and payers need before launch
  • Measurement-based care, outcome transparency and AI in psychiatry
  • Child and adolescent mental health, including Facts for Families topics
  • Mentalization-based treatment, personality disorders and self-harm in young people
  • Physician mental health, burnout and lived experience

RECENT COVERAGE

In the press.

PRESS CONTACT

On deadline?

Email is fastest. Say who you are, the outlet and the deadline, and we will get back to you the same day where we can.

info@macmillanmuir.com